Treatment of Cogan's Syndrome with Moderate to Severe Cochleo-Vestibular Involvement

Cochleo-vestibular involvement in Cogan's syndrome carries a poor prognosis and requires rapid, appropriately escalated treatment. This protocol addresses patients with moderate to severe severity of this involvement.

Clinical Scenario

In Cogan's syndrome, cochleo-vestibular disease — unlike ocular involvement — tends to progress rapidly and is associated with a poor outlook for auditory and vestibular function. When severity reaches a moderate to severe threshold, the clinical situation justifies prompt initiation of intensified treatment strategies.

Therapeutic Approach

This protocol incorporates biologic therapy as a treatment avenue for moderate to severe cochleo-vestibular involvement. Specific agent selection and the full management sequence are defined in the complete structured protocol.

Full regimen details — including agent choice, sequencing, and clinical decision points — are available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.revmed.2024.09.007

Unlike ocular involvement, cochleo-vestibular involvement has a poor prognosis and justifies the rapid introduction of immunosuppressive treatment or biologic therapy.
Data on other biologic therapies is even more limited; five isolated cases report the efficacy of tocilizumab, and two cases of rituximab.

View source ↗